Clapham, John C (2020) Sixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now? In: Type 2 Diabetes Methods and Protocols : methods in molecular biology. Humana Press, New York, pp. 1-30. ISBN 9781493998807
|
Text
__TAIPAN_john.clapham_Documents_002 SCIENCE_BOOK CHAPTER_BOOK CHAPTER CLAPHAM.pdf Download (346kB) | Preview |
Abstract
The control of blood glucose is a dynamic interplay involving several complex systems. In diabetes these systems are perturbed, resulting in a disease continuum of progressive decline over many years. Today, excluding insulin, there are eight classes of anti-diabetic agent which have taken over 60 years to add to the pharmacy chest. In this review I have examined each of these classes with some bias towards drug discovery thinking. Based on history, future science here will be strong, progressive and innovative; the huge test for industry is their response to enormous challenges besetting drug discovery and successfully turn the drug discovery praxis into affordable, effective and safe medicines.
| Item Type: | Book Section |
|---|---|
| Uncontrolled Keywords: | Type-2-diabetes Drug discovery Metformin Sulfonylureas Biguanides Thiazolidinediones α-Glucosidase inhibitors DPPIV inhibitors GLP-1 SGLT2 inhibitors Pharmaceutical industry |
| Subjects: | R Medicine > RM Therapeutics. Pharmacology |
| Divisions: | School of Science > Metabolic Research |
| Depositing User: | John Clapham |
| Date Deposited: | 10 Mar 2020 15:02 |
| Last Modified: | 31 Jan 2022 01:15 |
| URI: | http://bear.buckingham.ac.uk/id/eprint/443 |
Actions (login required)
 |
View Item |
